Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.45 |
| ▸ | AKT1 | P31749 | 5/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8353081 | 0.98 | DRD2 (0.54) | DRD2HDAC4HSD11B1AKT1SLC6A2 | |
| SCHEMBL13012452 | 0.90 | DRD2 (0.49) | DRD2HDAC4HSD11B1AKT1SLC6A2 | |
| SCHEMBL1975025 | 0.87 | HSD11B1 (0.56) | HDAC4HSD11B1OPRM1OPRL1ALDH1A1 | |
| SCHEMBL27594934 | 0.86 | DRD2 (0.59) | DRD2HDAC4HSD11B1AKT1OPRM1 | |
| SCHEMBL4219088 | 0.84 | OPRM1 (0.42) | DRD2HSD11B1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4005636 | 0.84 | DRD2 (0.58) | DRD2HDAC4HSD11B1AKT1OPRM1 | |
| SCHEMBL10002416 | 0.84 | HDAC4 (0.59) | HDAC4HSD11B1OPRM1OPRL1ALDH1A1 | |
| SCHEMBL5862774 | 0.84 | HDAC4 (0.64) | HDAC4HSD11B1SLC6A4SLC6A3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4451578 | 0.83 | DRD2 (0.56) | DRD2HDAC4HSD11B1AKT1OPRM1 | |
| SCHEMBL8636887 | 0.83 | OPRM1 (0.48) | HSD11B1SLC6A2SLC6A4SLC6A3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8680102-B2 | Pyrrole derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2014-03-25 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2283008-B1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-20110152320-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| EP-2286811-A1 | Chemokine receptor antagonists and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009141532-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141533-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | WO | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152320-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | DRD2 79/4885HDAC4 4368/4885HSD11B1 2866/4885 |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | DRD2 3566/4885HDAC4 2530/4885HSD11B1 589/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885HDAC4 2522/4885HSD11B1 729/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885HDAC4 2522/4885HSD11B1 729/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | DRD2 3542/4885HDAC4 2831/4885HSD11B1 352/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885HDAC4 2522/4885HSD11B1 729/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | DRD2 1061/4885HDAC4 432/4885HSD11B1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.